Abstract
To report the trends of immunosuppressive drug use for non-infectious uveitis and explore their relationship with industry payments.
A retrospective review of ophthalmologists reimbursed by Medicare for the administration of adalimumab (ADA), repository corticotropin (RCI), methotrexate (MTX), and mycophenolate mofetil (MMF) between 2014 and 2018.
A total of 316 ophthalmologists were reimbursed by Medicare for 1567 ADA, 465 RCI, 1752 MTX, and 12 333 MMF administrations. The number and dollar amount of industry payments were positively associated with ADA and RCI use (
< 0.001). From 2014 to 2018, there was a positive trend in the proportion of ADA (
= 0.007) and RCI (
= 0.007) used and negative trend in the proportion of MMF (
= 0.025) used.
From 2014 to 2018, the use of ADA and RCI increased while MMF decreased and MTX remained stable. There was a positive association between ADA and RCI use and physician-industry interactions. A causal relationship is not determined.